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CLINICAL INVESTIGATION
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Influence of antiidiotypic antibody activity on renal transplant out-
come. The presence of cytotoxic HLA antibodies (Abi) against donor
lymphocytes in pretranspiant sera is almost always associated with
rapid rejection of the renal transplant. We have investigated the
possibility that antiidiotypic antibodies (Ab2) to cytotoxic HLA anti-
bodies might modulate the immune response and favorably influence
renal allograft outcome. The role of antibodies (Ab3) which potentiate
the cytotoxic effect of Ab I was also studied. Pretransplant sera from 63
patients were tested for inhibitory or potentiating activity in the short
antiidiotypic assay. Inhibitory activity was detected in 30 patients and
in 28 the transplant survived more than a year. Of patients without
antibody activity II of 17 had grafts surviving more than one year, and
of those showing potentiating activity 11 of 16 were functioning at a
year. The difference in transplant survival between the first group and
the other two groups was statistically significant (P < 0.05). There was
no significant difference in survival rates between the latter two groups.
Potentiating activity is therefore not an independent predictor of
transplant failure, whereas the presence of antiidiotypic antibody
activity did correlate with improved allograft survival.
Renal transplantation is the treatment of choice for patients
with end-stage renal disease. The number of patients awaiting
transplantation in both USA and Europe is rising each year.
Despite therapy with potent immunosuppressive agents includ-
ing azathiopnne, prednisolone and cyclosporin A, a recent large
study has shown that around 20% of first cadaver grafts are lost
in the first year [1]; this figure is higher for recipients of second
or subsequent grafts. In all but a very few instances graft loss
occurs as a result of immunologic rejection.
Blood transfusions given to the recipient in the months and
years before transplantation have been shown to improve
allograft survival [2]. The mechanism of this beneficial blood
transfusion effect is unclear but it may be due to the induction
of suppressor cells [3, 4] clonal deletion [5], the production of
alloantibodies [6, 7] or antiidiotypic antibodies [4, 8—10].
Lymphocytotoxic antibodies may also develop following
transfusions, pregnancies or failed transplants [11, 12]. If they
are present before transplantation and directed to HLA anti-
gens expressed on donor lymphocytes (a positive crossmatch
Received for publication April 9, 1990
and in revised form January 29, 1991
Accepted for publication February 14, 1991
© 1991 by the International Society of Nephrology
test) the transplant almost inevitably fails. In a small group of
patients such antibodies can be detected in sera obtained
several months before, but not immediately before, transplan-
tation. One study has shown that the decline in cytotoxicity has
been associated with the development of antiidiotypic antibod-
ies (Ab2) to cytotoxic antibodies (Abl); patients who developed
such antibodies tolerated their graft well. In others, pretrans-
plant serum appeared to potentiate the cytotoxic activity in
their stored serum, anti-antiidiotypic antibodies' (Ab3) were
said to be present and transplants given to these patients
underwent early rejection [10]. Data from other investigators
have indicated that the cellular immune responses to HLA
antigens may be suppressed by antiidiotypic autoimmune reac-
tions [4, 8].
Previous sensitization to donor HLA antigens cannot, how-
ever, be detected in the majority of allograft recipients before
transplantation; transient cytotoxicity may have occurred but
remained undetected. It is possible therefore that these patients
have antibodies of the idiotypic-antiidiotypic network in their
pre-transplant sera which might influence the success of a
subsequent transplant. In this study we sought to determine
whether the presence of such antibodies in this larger group of
patients correlated with renal allograft survival.
Methods
Patients and materials
Patients. We studiej 86 transfused patients who had received
renal transplants from cadaver donors. Patients and donors
were tissue typed for HLA-A,B and -DR antigens using con-
ventional techniques [13]. Transplants were carried out when
the standard NIH crossmatch test using donor splenocytes as
targets was negative using both current and stored sera. Twen-
ty-three patients were excluded from the study for one of the
following reasons: (1) three patients died with a functioning
graft in less than a year; (2) one patient, who had undergone
hyperacute rejection, had a positive crossmatch on testing for
this study; and (3) 19 patients had alloantibody in their pretrans-
plant sera detected either by Cellular ELISA or AHG-CDC. No
patients therefore, who had alloantibody activity in their pre-
transplant serum were included in the study. Sixty-three pa-
tients were studied; 50 had transplants which survived more
than a year and in 13 cases the transplants failed within a year.
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No serum showed cytotoxic activity against lymphocytes from
any of the 24 panel cells. Immunosuppression was either with
azathioprine and prednisolone (30 patients) or cyclosporin A (33
patients). None of the patients had received immunoglobulin as
prophylactic therapy for CMV infection.
Sera. (1.) Serum samples obtained from each patient within
the 12 hours before transplant were heat inactivated at 56°C for
45 minutes and ultracentrifuged at 100,000 g for 60 minutes to
remove immune complexes before storage at —70°C. All sera
were tested in the complement dependent cytotoxicity assay
(CDC) against donor lymphocytes at the time of transplantation
and against target cells selected for this study.
(2.) Cytotoxic tissue typing sera were obtained for use as Abi
in the short antiidiotypic assay (SAA) from the United Kingdom
Transplant Service (Bristol, UK).
(3.) Serum samples used to dilute the tissue typing sera (Abi)
in the short antiidiotypic assay (SAA) were obtained from
untransfused male volunteers (Normal Male Serum-NMS) who
(a) shared no HLA antigens with the donor of the target
lymphocytes used in each assay and (b) possessed none of the
HLA antigens detected by the cytotoxic serum (Abl). These
normal male sera were also used as negative controls in CDC,
AHG-CDC and the Cellular ELISA. NMS was selected in this
way to prevent inhibition of cytotoxic serum by soluble HLA
antigens [14]. In addition the NMS itself had no activity in any
of the assays used.
Target lymphocytes
Venous blood samples (20 ml) collected in lithium heparin
containers were obtained from tissue typed normal volunteers
possessing the HLA antigens of the cadaver donor which were
not shared with the recipient. Peripheral blood lymphocytes
(PBLs) were prepared by Ficoll sodium diatrizoate (Flow
Laboratories, Irvine, UK) density-gradient centrifugation of the
whole blood and separated into T and B lymphocytes using a
nylon wool column [15].
Methods
All sera were tested in the following assays against all target
cells. Complement dependent cytotoxicity (CDC) [13], Cellular
enzyme-linked immunospecific assay (CELISA) [16], anti-hu-
man globulin complement-dependent cytotoxicity assay (AHG-
CDC) [17].
Short antiidiotypic assay (SAA)
Sixty-three sera obtained before transplantation were tested
for inhibitory (Ab2) or potentiating (Ab3) activity in the SAA
using cytotoxic tissue typing sera to the donor HLA antigens
mismatched with the recipient as AbI containing sera. Lym-
phocytes from members of a normal panel were used as target
cells in the short antiidiotypic assay. One hundred and fifty-
eight sera/cell combinations were tested. All but 4 of the 30
panel members were heterozygous for HLA antigens.
The short antiidiotypic assay (SAA) was performed as de-
scribed previously [18, 19]. Briefly, an aliquot of tissue typing
serum directed towards one of the donor HLA antigens not
shared with the recipient was serially diluted with recipient sera
obtained immediately before transplant (Pre); a further aliquot
was diluted (neat to 1/64) with normal male serum (NMS) as a
control. Two microliters of the mixture were then transferred to
wells of a microtest plate and incubated overnight at 4°C. Panel
target PBL or purified B lymphocytes (5 X l0/ml) bearing the
unshared antigen were added to each well, and the standard
long incubation complement-dependent micro-lymphocytotoxic
assay performed. All tests were performed in duplicate and the
results read by an independent observer. We have previously
confirmed that inhibition detected using the SAA is similar to
that observed using inhibition of cytotoxicity by the chromium
release method [20].
Antiidiotypic activity was calculated in the standard way [10,
18] as the percentage end-point inhibition (%EI) using the
formula:
%EI
for example,
(Abi + NMS) — (Abl + Pre)
(Abl + NMS)
(80 — 0)%EI= xl00100%
x 100
A difference of <50% El between the normal male serum (Abl
+ NMS) and the serum obtained before the transplant (Abl +
Pre) was considered negative, while a difference of 50% El
was considered evidence of antiidiotypic activity provided cell
kill in the control wells were 50%.
Potentiating activity (Ab3) was considered to be present
when (AbI + Pre) showed a 50% cell kill when compared with
(Abi + NMS) in the last dilution in which cytotoxic activity
was detected. The %EI formula was used as it is the standard
way in which others [10, 18] have estimated antiidiotypic
activity. In addition we noted that in all but three positive
seralcell combinations inhibition occurred over at least two
dilutions (Table 4).
IgG fractions and F(ab')2 fragments from sera with inhibitory
activity in SAA were prepared as described elsewhere [19]. One
band (150 kDa) was present when the gel was run under
non-reducing conditions and two bands (50 kDa and 20 kDa)
were present when the gel was run under reducing conditions.
The preparations, identified by immunodiffusion as IgG, were
tested in the short antiidiotypic assay. Purity of the F(ab')2
fragment was confirmed by SDS-PAGE. The F(ab')2 prepara-
tion was then tested in the short antiidiotypic assay.
Statistical analysis
Statistical analyses were performed using the chi squared test
with Yates' correction, Fisher's exact test and Student un-
paired I-test.
Results
Overall transplant survival at one year was 79%, and graft
outcome was not influenced by the number of HLA antigens
mismatched between donor and recipient. In addition there was
no significant correlation between allograft survival and the
type of post-transplant immunosuppression or the number of
transfusions administered before transplantation (mean 12
10). Eighty-two percent of first grafts were functioning at one
year compared with 57% of second or subsequent transplants;
this difference was not significant (X2 with Yate's correction =
1.13).
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Fig. 1. Inhibitory activity in serum fraction from 2 patient's sera
showing that inhibitory activity resides in the F(ab')2 fragments of the
IgG fraction. Inhibition occurred from 1:2 to 1/16 dilution of serum.
Symbols are: (0) IgG; (0) F(ab')2; (0) non-IgO.
Table 1A. The influence of antiidiotypic antibodies (Ab2) and
potentiating activity (Ab3) on renal allograft survival rates
Survival
Total
Survivors
%>1 year <1 year
Ab2 activity 28 2 30 93
Ab3 activity 11 5 16 68"
No Ab activity 11 6 17 65
a P < 0.05 (chi square test with Yates' correction) when compared
with survival in those with no Ab activity
b P NS (chi square test with Yates' correction) when compared
with survival in those with no Ab activity
Table lB. The influence of antiidiotypic antibodies (Ab2) and
potentiating activity (Ab3) on primary renal allograft survival rates
Survival
Total
Survivors
%>1 year <1 year
Ab2 activity
Ab3 activity
26
9
1
3
27
12
96
75b
No Ab activity 11 6 17 65
a P < 0.02 (chi square test with Yates' correction) when compared
with survival in those with no Ab activityb p = NS (chi square test with Yates' correction) when compared
with survival in those with no Ab activity
IgG fractions were prepared from two sera showing inhibi-
tory activity. In both cases activity was shown to reside in the
F(ab')2 fragment of the IgG serum fraction (Fig. 1).
Activity in the short antiidiotypic assay (SAA)
Pretranspiant sera from 63 patients which showed no alloanti-
body activity in any of the binding assays used were tested in
Table 2. Patients with no antibody activity
No. of
Pt. mismatches Abl tested Not tested
MM64 1 A24 —
AK8I 5 A2/B13/B40 A31/DRI
JM86 4 A24/A29/B7/B44 —
WRIO7 4 A1/B7/B8/DR2 —
TBIO3 2 Al/Bl7 —
1M91 2 B40/B49 —
023 3 A3/B 14/DR7 —
029 2 A2/B12 —
08 3 B8/B l2/DR3 —
02 4 A19/B17/B37 DRw6
GSl24 2 A2 B5
ABS 5 B14/B27/DR5 A33/DRw6
FWS& 4 B 12 A9/DR2/DR4
Wp93a 2 A26/B17 —
AC96 4 A2/A28/B44 DR4
AC74 4 A9/Al1/B15 DR2
FW94 3 A26/B14 Bw57
a Patients whose grafts failed in less than one year
the SAA for inhibitory (Ab2) or potentiating (Ab3) activity.
Cytotoxic tissue typing sera to panel lymphocytes carrying
donor HLA class I or class II antigens not shared with the
recipient sera were used as Ab 1 containing sera. Sera from 30
(47.6%) patients showed inhibitory activity against at least one
of the target cells tested. Twenty-eight of the transplants were
functioning one year later and two had failed (Table lA). One of
the patients in the latter group had had two previous grafts
which failed, whereas only one of the 28 in the former group had
had a previously unsuccessful transplant. One hundred and
twenty-three seralcell combinations from 47 patients showed
either inhibitory or no activity in the SAA. In only two sera/cell
combinations did inhibition fall between 50% and 55%, indicat-
ing a clear distinction between the presence and absence of
antibody activity in 1% of the sera/cell combinations (Fig. 2).
Seventeen patients showed neither inhibitory nor potentiat-
ing activity in their pre-transpiant sera in 42 sera/cell combina-
tions tested (Table 2). Eleven transplants from these patients
survived one year and six failed. The difference in allograft
survival between those with inhibitory (Ab2) activity and those
with no activity in their pretransplant serum was statistically
significant (P < 0.05); the difference remained significant (P <
0.02) when data from recipients of primary grafts were consid-
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Fig. 2. Data point graph of %EI values in 123 sera/cell combinations
(i.e. all results except those where potentiating activity noted).
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Table 3. The effect of HLA mismatches and the number of blood
transfusions on the antibody development
Ab2 activity Ab3 activity No Ab activity
HLA
mistmatchesa
A 1.4 0.7 1 0.8 1.4 0.6
B 1.4 0.6 1.3 0.6 1.4 0.6
DR 0.6 0.6 0.7 0.6 0.8 0.7
No. of blood 12.8 10.6 13.2 10.3 12.8 11.8
transfusionsa
a No statistical difference between these values
ered (Table IB). There was no significant difference in the
number of HLA mismatches, or the number of previously
administered blood transfusions, in those showing Ab2, Ab3
and no antibody activity (Table 3).
Potentiation of lymphocytotoxicity (Ab3 activity) was
present in pretranspiant sera from 16 patients. Since we had
previously shown that several sera showing low grade lympho-
cytotoxicity detected only in the AHG-CDC assay could mimic
potentiating activity in the SAA [9, 191, all 16 sera were tested
in AHG-CDC, but none of the sera/cell combinations tested was
positive. Grafts in 11 of the 16 patients belonging to this group
survived for one year and five failed. There was no significant
difference in transplant survival between those showing poten-
tiating activity and those in whom no antibodies were detected
(Table 1A).
Only 38 of 196 sera/cell combinations were not tested; this
was either because there was insufficient serum from a given
patient or because we could not obtain tissue typing sera (AbI)
of sufficiently high titer when diluted with whole serum; in three
of the 38 seralcell combinations, the pretransplant sera were
cytotoxic to the target cell chosen (although negative in initial
panel screening) and hence could not be tested for Ab2 activity.
In most patients Ab2 or Ab3 activity was not present against
Abl to all donor antigens (Tables 4 and 5); this suggests that
activity was specific. In patients showing no antibody activity,
42 seralcell combinations were tested. Twelve were not tested
in this group for the reasons given above (Table 2).
Post-transplant immunosuppression and allo graft survival
Transplant survival in those with Ab2, Ab3 or no antibody
activity in their pretransplant sera was evaluated according to
the immunosuppressive regime administered following trans-
plantation. In those with Ab2 activity 15 patients whose grafts
survived one year received azathioprine and prednisolone and
13 were given cyclosporin A; both of those whose transplants
failed were treated with cyclosporin A. There was no significant
statistical difference between the two groups (Table 6). Simi-
larly, the type of immunosuppression given to those showing
Ab3 activity had no influence on allograft survival. Cyclosporin
A, however, significantly influenced graft outcome in patients
without antibody activity in their pretransplant serum (P <
0.01; Table 6).
Discussion
This study shows that the presence of pretransplant inhibi-
tory activity in the short antiidiotypic assay is associated with
improved transplant outcome. Graft survival in patients show-
Table 4. Specificity of Ab2a activity
No. of Not
Pt. mismatches Ab2+(No.) Ab2— tested
GS7 2 B8(2) B35 —
HMIO 2 A1(2)/B27(2) — —
RFI4 3 B7(2) A24 Bw42
RG34 3 A2(l) B35/DR4 —
CR57 S A2(2) Al l/DR2/DR4 B40
JM59 3 Al(2) A28 B12
MD66 4 Al(2)/B50(2) A2 DR7
HS72 4 B7(2) A3/DR2 B47
FS77 3 B50(2) DR4 DR1
DM83 4 B7(2) A24/A26/88 —
LH84 4 A24(2) A26/B8 DR6
HC98 2 A3(l) — 814
AKIO2 4 Al(2) A2/B8 B45
AC1O9 3 Al(2) A32/B37 —
MM11O 4 A1(2) A32/B14/B37 —
AT1II 3 A3(2) B7/DR2 —
HM1I2 3 A3(1) B7 DR2
WAII4 5 A3(2)/Bl4(3) A26/B18IDR3 —
TW133 4 Aw19(3)
A29(3)/B5(2)
B44 —
DD73 3 B40(2) A24/A31 —
GI 2 A32(2) — DR8
G7 1 87(2) — —
G13 3 B14(3) B7 DR7
G17 1 B27(2) — —
G27 2 B5(2) — A28
G28 4 A2(2) A24/B27 B5
EF55 5 A3(2) A24/B7/B27 DR5
MF71 4 A3(2) B7/DR4 B47
SW132' 5 Aw19(2)1B5(2) A29/B44/DR2 —
G18' 3 B7(3) A3 B18
(No.) Number of doubling dilutions over which inhibition took place
(control cytotoxicity 50%).
a Ab2 sera diluted from neat to 1:64b Patients whose grafts survived less than 1 year
Table 5. Specificity of the potentiating antibodies (Ab3)
Pt.
No. of
mismatches AB3+ Ab3—
Not
tested
FM92 4 A2 B49/DR5 B40
AWIOO 4 A2/B44 835 A32
AJIO1 4 Al B17 B45/DR3
AMI2I 5 A24 A11/B7/B35 DR4
GH54 4 A24/B27 DR4/DR5 —
G9 I B22 — —
G6 I B5 — —
Gil I B14 — —
G25 I B2 — —
HD32 I All — —
G5 3 Al A32/B44 —
RH88 4 B35 A3/B8 DRw6
CR115 4 B18 A26/B14/DR3 —
DM I30 3 B44 A2 DRw6
WT118 2 B27 DR2 —
G3 3 Al — B13
a Patients whose grafts failed in less than one year
ing antiidiotypic activity was significantly better than in those
showing either potentiating activity or no antibody activity in
their pretransplant serum. There was no difference in graft
survival between those whose sera showed potentiating activity
and those with no antibody activity at all in their pre-transplant
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Table 6. The influence of post-transplantation immunosuppressive
regime on allograft survival
Percent of patients with
a functioning graft
at one year P
Ab2 Activity: CsA
A + P
87% (13/15)
100% (15/15)
NS
Ab3 Activity: CsA
A + P
64% (7/11)
80% (4/5)
NS
No antibody activity: CsA
A + P
100% (7/7)
40% (4/10)
<0.Ola
Abbreviations are: CsA, cyclosporin A; A ÷ P, azathioprine +
prednisolone.a Fishers' exact test
sera. This indicates that potentiating activity in the short
antiidiotypic assay was not an independent predictor of trans-
plant failure in those patients who were not highly sensitized.
Numerous studies have shown a beneficial effect of donor
specific and third party blood transfusions in improving survival
of renal allografts from living-related and cadaveric donors,
respectively [21, 22]. Why transfusions improve allograft sur-
vival is unclear. We have already shown that noncytotoxic Fc
receptor blocking antibodies occur after third party transfusion
before cadaver donor transplantation and after donor specific
transfusion [6, 23]. The presence of such antibodies in pretrans-
plant sera correlates with improved renal allograft survival
particularly when recipients are less well matched for HLA
antigens with their donors. Such antibodies, however, are not
present in pretransplant sera from all patients with successful
graft outcome, and hence we have sought the presence of
antiidiotypic activity in such sera.
In addition, noncytotoxic sera obtained from transfused
dialysis patients were able to decrease the cytotoxic activity of
autologous sera obtained when the patients were highly sensi-
tized [19], and in some patients this activity was directed
towards specific anti-HLA antibodies. The development of
antiidiotypic activity may thus explain why fluctuating titers of
cytotoxic antibodies are found in sera from sensitized patients.
The present study, in contrast, describes patients in whom
cytotoxic antibodies to donor cells have not been demon-
strated, and in that way they resemble the majority of patients
awaiting transplantation. Tissue typing sera, therefore, were
used as Abi and presence of Ab2 was found to have a similar
favorable effect on graft outcome; the presence of Ab3 did not
prejudice transplant survival. It may be that different types of
Ab3 exist as has been demonstrated in animal studies [24].
Allograft survival in patients showing inhibitory activity in
the short antiidiotypic assay was 93% at one year (96% when
those receiving a first graft were considered alone) and no
additional beneficial effect of giving cyclosporin A was found.
Cyclosporin A was noted to improve transplant outcome only in
patients in whom neither Ab2 nor Ab3 were found before
transplantation. This suggests that the development of antiidio-
typic antibodies might be one of the mechanisms by which
transfusions improve renal transplant outcome.
Furthermore, using the rather laborious mixed lymphocyte
reaction technique, antiidiotypic activity has been shown to
occur after blood transfusion in human and animal models [8,
25]. In clinical transplantation Reed et a! [10] have shown that
the occurrence of such antibodies before transplantation corre-
lated with improved transplant survival in a small group of
patients. These authors suggest that such antibodies may be
part of the mechanism of the beneficial effect of blood transfu-
sion in transplantation. Antiidiotypic activity has also been
detected by inhibition of lymphocytotoxicity using the F(ab')2
fragment of the IgG fraction of serum obtained after transfusion
and during successful pregnancy [9, 14, 26, 27]. The SAA is a
modified form of the latter assay in which antiidiotypic activity
is sought in whole serum rather than in serum fractions; it can
therefore be performed more rapidly [18, 28]. Patients awaiting
transplantation could be screened for Ab2 activity against a cell
panel using this simple method. Any HLA antibodies against
which Ab2 was directed would be noted and a donor bearing the
corresponding HLA antigens could be selected for that patient.
A study currently being undertaken in our laboratory indicates
that over half the patients awaiting transplantation have Ab2
against cytotoxic tissue typing sera to commonly occurring
HLA antigens.
It is possible that noncytotoxic alloantibodies or nonspecific
rheumatoid factors could block the activity of cytotoxic anti-
bodies and thus mimic antiidiotypic activity in the SAA. In this
study, therefore, all sera were screened for alloantibody activ-
ity using a sensitive Cellular ELISA and AHG-CDC; any that
were positive were excluded from analysis. Moreover, the
inhibitory or the potentiating activity was not directed to all
HLA antibody specificities in most patients studied, suggesting
that this type of activity is specific. In the present study and in
our previous work we have shown inhibitory activity to reside
in the F(ab')2 fragment of the IgG fraction of serum which
makes nonspecific inhibition by rheumatoid factors unlikely.
The antibodies we have demonstrated appear to have their
effect by inhibiting other antibodies. Since activity due to
immune complexes, soluble antigens and alloantibodies has
been excluded, the most likely candidates are antiidiotypic
antibodies, as others who work in this field using similar
techniques have deduced [10, 14]. It is, however, possible that
antibodies could inhibit the activity of other antibodies in
different ways.
Antiidiotypic antibodies (Ab2) are believed to act by binding
to determinants within the variable region of the combining site
of HLA antibodies (Abl). In animal models, it had been
suggested that Ab2 can inhibit the binding of Abl to HLA
antigens and that other immunosuppressive properties of Ab2
may be mediated by their ability to bind to the variable region
of idiotypic receptors expressed on activated T lymphocytes
and to suppress the proliferation of B lymphocytes producing
Abl [24, 28]. This has been suggested recently as a possible
mechanism of action of Ab2 in clinical transplantation [29].
The existence of Ab3 or "anti-antiidiotypic" antibodies has
been proposed by Jerne in his original network hypothesis [30].
Reed and co-workers have proposed that non cytotoxic sera
might contain Ab3 which could mediate the release of Ab 1 from
Abl-Ab2 complexes present in the Abi positive sera, thus
potentiating its cytotoxic activity [10]. In the present study we
were able to detect potentiating activity in sera from 16 pa-
tients, and although graft survival in this group was worse than
in those showing Ab2 activity, it was not significantly different
from those in whom no antibody activity was detected (Table
2A). Furthermore, we have previously found potentiating ac-
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tivity in sera from patients who had received donor specific
transfusion, and all subsequent transplants from their specific
living-related donors were successful [9]. In our studies, there-
fore, potentiating activity did not prejudice transplant outcome.
Anti-antiidiotypic antibodies (Ab3) have been described pre-
viously as part of a network of antibody responses to transplan-
tation antigens in animal studies [24, 29]. Ab3 inhibited the
binding of Ab2 to Abl rather than the release of Abi from
Abl-Ab2 complexes [24, 31], and most of the Ab3 produced in
such animals was found to bind the original MHC antigen,
suggesting that the response in that model was idiotypic rather
than anti-antiidiotypic [24, 31]. Furthermore, no rejection was
observed in animals expressing a high titer of Ab3 in their sera
and who subsequently received a skin transplant [24]. The
effect of potentiating activity (Ab3) in sera obtained before
transplantation requires further investigation.
We conclude that antibodies of the idiotypic/antiidiotypic
network may be present before transplantation in patients who
have not previously shown cytotoxic activity to donor lympho-
cytes. The presence of inhibitory activity correlated with im-
proved allograft survival whereas potentiating activity was not
an indicator of poor transplant outcome. The rapidly performed
short antiidiotypic assay before transplantation may provide a
useful way of selecting patients for successful transplantation.
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